Quince Therapeutics Receives Nasdaq Noncompliance Notice, Gets Time Through Oct. 15 To Regain Compliance
SEC.
Stocks · News reference
8-K/A filing — Quince Therapeutics, Inc. (QNCX)
Filed: 2026-06-26 AccNo: 0001193125-26-285572 Size: 147 KB Item 3.03: Material Modifications to Rights of Security Holders
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Quince Therapeutics, Inc. (QNCX)
Filed: 2026-09-04 AccNo: 0001193125-26-382838 Size: 140 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Cantor Fitzgerald Reiterates Overweight on Quince Therapeutics, Maintains $70 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Quince Therapeutics (NASDAQ:QNCX) with a Overweight and maintains $70 price target.
Quince Therapeutics Q2 EPS $(12.31) Beats $(26.32) Estimate
Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(12.31) per share which beat the analyst consensus estimate of $(26.32) by 53.21 percent. This is a 81.9 percent increase over losses of $(68.00) per share